News

Recruitment for At Home Immuno-T Validation Study Complete

In January 2022 ImmunoServ launched its trial of the Worlds first At-Home combined COVID-19 T cell and antibody test. Participants from across the UK were invited to sign up to the validation study. Within 10 weeks more than 300 participants have been recruited.

Read More

ImmunoServ Appoints New CEO

ImmunoServ is pleased to announce the appointment of Dr James Hindley as our new Chief Executive Officer. James brings a wealth of immunology and entrepreneurial experience in guiding biotech ventures; his proven leadership in the field is an excellent fit for ImmunoServ’s mission to provide expert immunology services to the world.

Read More

Double Certification: ISO 9001 and Cyber Essentials

ImmunoServ is delighted to announce that the company’s commitment to Quality Assurance and Cyber Security has been independently verified.

Read More

Omicron T cell test under development

Following the WHOs announcement about the new SARS-CoV-2 Omicron variant of concern (VoC) on 26 November 2021, the team here at ImmunoServ have started working on a T cell immune response test for this variant. This rapid development demonstrates the flexibility of our T cell testing platform and the dedication of our company to help in the ongoing fight against COVID-19.

Read More

Single blood test to measure T-cell and antibody response to SARS-CoV-2

ImmunoServ have been featured by Cardiff University for our work on a test to measure both the T-cell and antibody response to SARS-CoV-2 in a single blood sample.

Read More

Incorporation

We are delighted to announce the incorporation of ImmunoServ Ltd., a specialist contract research organisation in the immunology sector.

Read More

To stay updated on our latest news, please sign up to our newsletter.

Call or Email

Social Media

Recruitment for At Home Immuno-T Validation Study Complete

In January 2022 ImmunoServ launched its trial of the Worlds first At-Home combined COVID-19 T cell and antibody test. Participants from across the UK were invited to sign up to the validation study. Within 10 weeks more than 300 participants have been recruited.

Read More

ImmunoServ Appoints New CEO

ImmunoServ is pleased to announce the appointment of Dr James Hindley as our new Chief Executive Officer. James brings a wealth of immunology and entrepreneurial experience in guiding biotech ventures; his proven leadership in the field is an excellent fit for ImmunoServ’s mission to provide expert immunology services to the world.

Read More

Double Certification: ISO 9001 and Cyber Essentials

ImmunoServ is delighted to announce that the company’s commitment to Quality Assurance and Cyber Security has been independently verified.

Read More

Omicron T cell test under development

Following the WHOs announcement about the new SARS-CoV-2 Omicron variant of concern (VoC) on 26 November 2021, the team here at ImmunoServ have started working on a T cell immune response test for this variant. This rapid development demonstrates the flexibility of our T cell testing platform and the dedication of our company to help in the ongoing fight against COVID-19.

Read More

Single blood test to measure T-cell and antibody response to SARS-CoV-2

ImmunoServ have been featured by Cardiff University for our work on a test to measure both the T-cell and antibody response to SARS-CoV-2 in a single blood sample.

Read More

Incorporation

We are delighted to announce the incorporation of ImmunoServ Ltd., a specialist contract research organisation in the immunology sector.

Read More

If you’re keen to work with us in achieving our vision please get in touch.